181 related articles for article (PubMed ID: 24159006)
1. Practice tips and tools for the successful use of U-500 regular human insulin: the diabetes educator is key.
Cochran EK; Valentine V; Samaan KH; Corey IB; Jackson JA
Diabetes Educ; 2014; 40(2):153-65. PubMed ID: 24159006
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of U-500 regular insulin: review and meta-analysis.
Reutrakul S; Wroblewski K; Brown RL
J Diabetes Sci Technol; 2012 Mar; 6(2):412-20. PubMed ID: 22538155
[TBL] [Abstract][Full Text] [Related]
3. Translating U-500R Randomized Clinical Trial Evidence to the Practice Setting: A Diabetes Educator/Expert Prescriber Team Approach.
Bergen PM; Kruger DF; Taylor AD; Eid WE; Bhan A; Jackson JA
Diabetes Educ; 2017 Jun; 43(3):311-323. PubMed ID: 28427304
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
de la Peña A; Riddle M; Morrow LA; Jiang HH; Linnebjerg H; Scott A; Win KM; Hompesch M; Mace KF; Jacobson JG; Jackson JA
Diabetes Care; 2011 Dec; 34(12):2496-501. PubMed ID: 21994429
[TBL] [Abstract][Full Text] [Related]
5. TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL.
Hood RC; Arakaki RF; Wysham C; Li YG; Settles JA; Jackson JA
Endocr Pract; 2015 Jul; 21(7):782-93. PubMed ID: 25813411
[TBL] [Abstract][Full Text] [Related]
6. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES β-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS.
Mari A; Rosenstock J; Ma X; Li YG; Jackson JA
Endocr Pract; 2015 Dec; 21(12):1344-52. PubMed ID: 26307903
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
[TBL] [Abstract][Full Text] [Related]
8. [Clinical aspects of Insulin Lispro (LY275585)].
Kuzuya T
Nihon Rinsho; 1997 Nov; 55 Suppl():298-305. PubMed ID: 9434484
[No Abstract] [Full Text] [Related]
9. The use of U-500 regular insulin in the management of patients with obesity and insulin resistance.
Jones P; Idris I
Diabetes Obes Metab; 2013 Oct; 15(10):882-7. PubMed ID: 23489348
[TBL] [Abstract][Full Text] [Related]
10. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study.
Grunberger G; Bhargava A; Ly T; Zisser H; Ilag LL; Malone J; Fan L; Zhang S; Johnson J
Diabetes Obes Metab; 2020 Mar; 22(3):434-441. PubMed ID: 31865633
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Prestudy Insulin Therapy on Safety and Efficacy of Human Regular U-500 Insulin by Pump or Injection: A Posthoc Analysis.
Hood RC; Chen Y; Sindelar DK; Ly T; Juneja R; Pollom RD; Ilag L; Wysham C
Endocr Pract; 2021 Aug; 27(8):783-789. PubMed ID: 33515757
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
Ceglia L; Lau J; Pittas AG
Ann Intern Med; 2006 Nov; 145(9):665-75. PubMed ID: 17088580
[TBL] [Abstract][Full Text] [Related]
13. Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study.
Blevins T; Lane W; Rodbard D; Sindelar D; Fan L; Ellinor K; Ilag L; Ly T; Johnson J
Diabetes Technol Ther; 2021 Jan; 23(1):51-58. PubMed ID: 32631081
[No Abstract] [Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
Ma X; Benson CT; Prescilla R; Zhang S; Linnebjerg H; LaBell ES; Morrow LA; Jackson JA; Nguyen A; Ilag LL; Johnson JL; Leishman D
J Diabetes Sci Technol; 2022 Mar; 16(2):401-407. PubMed ID: 33242998
[TBL] [Abstract][Full Text] [Related]
15. Converting U-500 regular insulin to insulin detemir and insulin lispro in a patient undergoing dietary changes in preparation for bariatric surgery.
Nguyen KV; Weidner JA; Shaw KF; Valdez CA
Am J Health Syst Pharm; 2016 Mar; 73(5):292-7. PubMed ID: 26896501
[TBL] [Abstract][Full Text] [Related]
16. Simulation-Based Evaluation of Dose Titration Algorithms for U-500R Insulin by Pump in Subjects with Type 2 Diabetes.
Ma X; Waterhouse T; Ilag LL; Ly T; Juneja R; Garhyan P; Hardy T; Hood RC
J Diabetes Sci Technol; 2021 Sep; 15(5):1195-1197. PubMed ID: 34210191
[No Abstract] [Full Text] [Related]
17. [Insulin therapy in type 2 diabetes].
Hummel M
MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
[No Abstract] [Full Text] [Related]
18. Patient-reported outcomes in a study of human regular U-500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes.
Chen J; Fan L; Peng X; Ilag L; Ly T; Johnson J
Diabetes Obes Metab; 2021 Jan; 23(1):240-244. PubMed ID: 32893428
[TBL] [Abstract][Full Text] [Related]
19. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
20. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.
de la Peña A; Ma X; Reddy S; Ovalle F; Bergenstal RM; Jackson JA
J Diabetes Sci Technol; 2014 Jul; 8(4):821-9. PubMed ID: 24876428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
